Nuclear unphosphorylated STAT3 correlates with a worse prognosis in human glioblastoma

Area of Science:

• Oncology
• Molecular Biology
• Neuroscience

Background:

• Glioblastoma (GBM) is an aggressive brain tumor where STAT3 signaling is implicated.
• Previous studies on STAT3 modulation in GBM have yielded conflicting results.
• Understanding STAT3's role in gliomagenesis is crucial for developing effective treatments.

Purpose of the Study:

• To investigate the expression and localization of STAT3 and its phosphorylated forms in astrocytomas of varying grades, including GBM.
• To explore the correlation between STAT3 expression/localization and patient survival outcomes.
• To identify potential non-canonical pathways involved in STAT3 activation in GBM.

Main Methods:

• Immunohistochemistry was used to assess STAT3, pSTAT3 (Y705), and pSTAT3 (S727) expression in tissue microarrays.
• Specimens included non-neoplastic tissue, grade II and III astrocytomas, and GBM.
• MET expression was analyzed as a potential non-canonical pathway marker.

Main Results:

• STAT3 was overexpressed and showed increased nuclear localization in GBM compared to lower-grade astrocytomas and non-neoplastic tissue.
• Nuclear localization of phosphorylated STAT3 forms (pSTAT3 Y705, S727) did not differ significantly across tumor grades.
• Higher nuclear STAT3 levels correlated with reduced recurrence-free and overall survival, while phosphorylated forms did not.
• Increased MET expression was observed in tumors with higher STAT3 nuclear localization.

Conclusions:

• STAT3 nuclear translocation in GBM may be mediated by phosphorylation-independent mechanisms.
• Non-canonical pathways, potentially involving MET, may contribute to STAT3 activation in GBM.
• Nuclear STAT3, rather than its phosphorylated forms, is a potential prognostic marker for GBM and a target for therapeutic intervention.